Yerba mate Ilex paraguariensis A.St.-Hil.
Also called: mate, maté, Paraguay tea
Yerba mate is a caffeinated drink made from the dried leaves and small stems of an evergreen South American tree, consumed much like tea or coffee. Leaf extracts also appear in multi-ingredient supplements, often marketed for weight loss.
- Category
- Botanical
- Part used
- Leaves and small stems
- Strongest evidence
- C Limited
- Native range
- Native from Brazil to northeastern Argentina (POWO: "Brazil to NE. Argentina"; also Paraguay and Uruguay)
- Reviewed
- 2026-10-29
Class 1 Well studied in people. A 2025 meta-analysis (Front Endocrinol) included 13 RCTs of yerba mate (tea, extract or capsules) for metabolic outcomes; it excluded trials combining yerba mate with other plants or supplements. [9]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CSeveral areas, whole body or blood2 topics
CBlood sugar and weight1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Body fat in adults with obesity | C | A 12-week double-blind trial in 30 Korean adults with obesity (3 g/day) reported lower body fat mass, percent body fat and waist-hip ratio than placebo, without significant safety changes. [2] |
| Physiological effects (pooled evidence) | C | A 2023 systematic review of 32 studies reported effects on metabolism, antioxidant and inflammatory markers, but risk of bias was high in 22 studies and certainty ranged from moderate to very low. [3] |
| Overall clinical evidence | C | LiverTox states that the general health claims for yerba mate have not been shown in rigorously controlled and adequately powered clinical trials. [1] |
Main constituents: Methylxanthines (caffeine, theobromine, theophylline), with caffeine levels in drinks similar to tea and coffee; also polyphenols, flavonoids such as rutin and quercetin, and triterpene saponins [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 3 g/day of yerba mate in capsules for 12 weeks (obesity trial). [2]
- EU traditional-use monograph (fatigue): 2 to 4 g of comminuted leaf daily as herbal tea, corresponding to 1 g of herbal substance 3 times per day, adults only. [5]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score DABCDEA: well known causeE: unlikely cause
LiverTox likelihood score D: possible but rare cause of clinically apparent liver injury.
Details and sources - Pregnancy and breastfeedingEU monograph: there are no or limited data from use during pregnancy and lactation; use should be avoided during pregnancy and lactation.
1 statement in the profile.
Details and sources - Interactions with medicines2 listed
MAO inhibitors; Sedatives; sympathomimetic drugs
Details and sources - Cancer evaluations (IARC, NTP)1 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
EU (HMPC, traditional use, 6 May 2010), comminuted leaf as herbal tea, adults: for fatigue, daily dose 2 to 4 g, corresponding to 1 g herbal …
Details and sources
- Cancer risk: a 2018 meta-analysis (15 studies in the quantitative analysis) found mate drinking associated with higher odds of upper aerodigestive tract cancers (OR 2.24), regardless of drink temperature; more than 1 liter daily carried higher odds than less. [4]
- LiverTox notes that epidemiologic studies suggest long-term use may increase the risk of head and neck cancers. [1]
- Eight commercial brands contained high levels of carcinogenic polycyclic aromatic hydrocarbons (PAHs), including benzo[a]pyrene at 8.03 to 53.3 ng/g of dry leaves, which were released into both hot and cold infusions. [6]
- Excessive intake can cause caffeine-related effects such as palpitations, nervousness, headache and insomnia. [1]
- Liver: LiverTox likelihood score D (possible but rare cause of clinically apparent liver injury), based on a few published cases. [1]
- EU monograph contraindications: gastric and duodenal ulcers, cardiovascular disorders such as hypertension and arrhythmia, hyperthyroidism; use should be avoided during pregnancy and lactation. [5]
Interactions
| With | What happens |
|---|---|
| MAO-inhibitor drugs | The EU monograph states that people taking MAO inhibitors should use mate with caution. [5] |
| Sedatives and sympathomimetic drugs | Caffeine-containing preparations reduce sedative action and increase side effects caused by sympathomimetic drugs. [5] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- The EU monograph requires that the content of polycyclic aromatic hydrocarbons (PAH) be adequately controlled. [5]
Regulatory status
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [8]
- EU: the HMPC adopted a Community herbal monograph on mate leaf (6 May 2010) for traditional use for fatigue and sensation of weakness, and to increase urine flow as an adjuvant in minor urinary complaints. [5]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming yerba mate (Ilex paraguariensis) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- IARC: drinking mate that is not very hot is in Group 3 (Volumes 51 and 116; evaluated 2016); hot mate is listed under drinking very hot beverages at above 65 °C, which is in Group 2A (Volume 116). [P3]
- No NTP technical report on yerba mate (Ilex paraguariensis) was found (NTP technical reports checked 2026-10-29). [P9]
- A 2018 meta-analysis (15 studies in the quantitative analysis) found mate consumption associated with higher odds of upper aerodigestive tract cancer (OR 2.24; 95% CI 1.74-2.87), with no difference between cold/warm and hot/very hot mate. [P4]
- Mate leaves and infusions contained high levels of carcinogenic polycyclic aromatic hydrocarbons (total of 21 PAHs 536 to 2,906 ng/g dry leaves across 8 brands). [P5]
Liver (NIH LiverTox)
- LiverTox likelihood score D: possible but rare cause of clinically apparent liver injury. One well-described case (a 21-year-old man after 4 months of daily drinking) resolved within 2 months of stopping (chapter updated 2024-11-10). [P1]
Interactions with medicines
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of the dietary ingredient — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P7]
- Polycyclic aromatic hydrocarbons (PAHs), including benzo[a]pyrene — The EU herbal monograph requires the content of polycyclic aromatic hydrocarbons (PAH) to be adequately controlled. [P6]
- PAH analysis by GC/MS — A study of eight commercial brands measured 21 PAHs by gas chromatography/mass spectrometry and found very high concentrations of carcinogenic PAHs in leaves and in hot and cold infusions. [P5]
Supply and conservation
- IUCN Red List: Near Threatened (NT), via GBIF species API, retrieved 2026-10-29. [P8]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (HMPC, traditional use, 6 May 2010), comminuted leaf as herbal tea, adults: for fatigue, daily dose 2 to 4 g, corresponding to 1 g herbal substance 3 times per day; to increase urine flow, daily dose 2.5 to 5 g, corresponding to 2.5 g herbal substance 1 to 2 times per day. Not recommended under 18 years. [P6]
Pregnancy and breastfeeding
- EU monograph: there are no or limited data from use during pregnancy and lactation; use should be avoided during pregnancy and lactation. Caffeine crosses the placenta and is distributed in breast milk. [P6]
Sources for this profile
- NIH LiverTox (NIDDK). Yerba Mate (Last Update: 2024-11-10), 2024-11-10. ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (list last updated 2026-07-23): 'Mate, not very hot (drinking)' and 'Very hot beverages at above 65 °C (drinking)', 2026-07-23. monographs.iarc.who.int
- Mello FW, et al. Maté consumption association with upper aerodigestive tract cancers: a systematic review and meta-analysis. Oral Oncol 2018;82:37-47 (PMID 29909900), 2018-07. pubmed.ncbi.nlm.nih.gov
- Kamangar F, et al. High levels of carcinogenic polycyclic aromatic hydrocarbons in mate drinks. Cancer Epidemiol Biomarkers Prev 2008;17(5):1262-8 (PMID 18483349), 2008-05. pubmed.ncbi.nlm.nih.gov
- EMA/HMPC. Community herbal monograph on Ilex paraguariensis St. Hilaire, folium (EMA/HMPC/580539/2008, 6 May 2010), 2010-05-06. ema.europa.eu
- eCFR. 21 CFR 111.75 (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Ilex paraguariensis A.St.-Hil., 2026-10-29. api.gbif.org
- National Toxicology Program. Technical Reports (long-term toxicology and carcinogenesis studies), 2026-10-29. ntp.niehs.nih.gov
Sources
- NIH LiverTox (NIDDK). Yerba Mate (Last Update: 2024-11-10), 2024-11-10. ncbi.nlm.nih.gov
- Kim SY, et al. Anti-obesity effects of Yerba Mate (Ilex paraguariensis): a randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med 2015;15:338 (PMID 26408319), 2015-09-25. pubmed.ncbi.nlm.nih.gov
- José MFB, et al. Physiological effects of yerba maté (Ilex paraguariensis): a systematic review. Nutr Rev 2023;81(9):1163-1179 (PMID 36647770), 2023-08-10. pubmed.ncbi.nlm.nih.gov
- Mello FW, et al. Maté consumption association with upper aerodigestive tract cancers: a systematic review and meta-analysis. Oral Oncol 2018;82:37-47 (PMID 29909900), 2018-07. pubmed.ncbi.nlm.nih.gov
- EMA/HMPC. Community herbal monograph on Ilex paraguariensis St. Hilaire, folium (EMA/HMPC/580539/2008, 6 May 2010), 2010-05-06. ema.europa.eu
- Kamangar F, et al. High levels of carcinogenic polycyclic aromatic hydrocarbons in mate drinks. Cancer Epidemiol Biomarkers Prev 2008;17(5):1262-8 (PMID 18483349), 2008-05. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew. Ilex paraguariensis A.St.-Hil. (accessed 2026-10-29). powo.science.kew.org
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Li D, et al. Yerba mate and its impact on glycemic control and metabolic health: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2025;16:1641592 (PMID 41244043), 2025-10-30. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.